ATE510912T1 - Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle - Google Patents

Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle

Info

Publication number
ATE510912T1
ATE510912T1 AT04785714T AT04785714T ATE510912T1 AT E510912 T1 ATE510912 T1 AT E510912T1 AT 04785714 T AT04785714 T AT 04785714T AT 04785714 T AT04785714 T AT 04785714T AT E510912 T1 ATE510912 T1 AT E510912T1
Authority
AT
Austria
Prior art keywords
immunoglobulins
methods
compositions
single vector
vector constructs
Prior art date
Application number
AT04785714T
Other languages
English (en)
Inventor
Jianmin Fang
Karin Jooss
Jing-Jing Qian
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE510912T1 publication Critical patent/ATE510912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04785714T 2003-06-03 2004-04-26 Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle ATE510912T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/452,253 US7485291B2 (en) 2003-06-03 2003-06-03 Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US54055404P 2004-02-02 2004-02-02
PCT/US2004/012807 WO2004113493A2 (en) 2003-06-03 2004-04-26 Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site

Publications (1)

Publication Number Publication Date
ATE510912T1 true ATE510912T1 (de) 2011-06-15

Family

ID=33538948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04785714T ATE510912T1 (de) 2003-06-03 2004-04-26 Zusammensetzungen und verfahren zur verbesserten expression von immunglobulinen von einem einzigen vektor unter verwendung einer peptidschnittstelle

Country Status (6)

Country Link
US (1) US7485291B2 (de)
EP (1) EP1629095B1 (de)
JP (1) JP4755586B2 (de)
AT (1) ATE510912T1 (de)
CA (1) CA2525379A1 (de)
WO (1) WO2004113493A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK200101581A (da) * 2001-10-26 2003-04-27 Danfoss As Transceiverkredsløb til ultralydsflowmåler
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1765846A4 (de) * 2004-07-13 2010-02-17 Cell Genesys Inc Aav-vektorzusammensetzungen und ihr einsatz in verfahren zür erhöhung der immunoglobulin-expression
EP2573185A3 (de) * 2005-02-16 2013-06-05 Lentigen Corporation Lentivirusvektoren und deren Verwendung
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
CN101595228A (zh) 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
JP2008220302A (ja) * 2007-03-14 2008-09-25 Hiroshima Univ タンパク質蓄積による神経変性疾患治療薬物のスクリーニング系
EP2271763A2 (de) * 2008-04-03 2011-01-12 Yeda Research And Development Company Ltd. Verfahren zur expression eines polypeptids im gehirn und dazu fähige nukleinsäurekonstrukte
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
EP2141499A1 (de) * 2008-07-02 2010-01-06 Apoptec AG COPD-Diagnose
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現
BR112012010357B1 (pt) 2009-11-02 2022-05-24 Inovio Pharmaceuticals, Inc. Proteínas de consenso de vírus de doença de febre aftosa (fmdv), sequências de codificação para as mesmas e vacinas feitas a partir das mesmas
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
KR101329348B1 (ko) 2012-05-31 2013-11-15 대한민국 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
WO2014145951A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10612041B2 (en) 2014-03-21 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
DK3212786T3 (da) * 2014-10-28 2019-07-01 Acib Gmbh Kompakt og optimeret metaboliseringsvejsdesign i pichia pastoris
CN107849102B (zh) * 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
US11253612B2 (en) * 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
MX2021013218A (es) 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
EP3997226A1 (de) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
CN115552022A (zh) 2020-03-02 2022-12-30 特纳亚治疗股份有限公司 由心肌细胞表达的微rna控制的基因载体
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス， インコーポレイテッド プラコフィリン２遺伝子治療の方法および組成物
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
US20230190961A1 (en) 2021-10-20 2023-06-22 University Of Rochester Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells
CN114107390B (zh) * 2021-11-05 2023-10-24 中国科学院精密测量科学与技术创新研究院 一种用于表达抗体IgG1的rAAV载体及其应用
WO2023201207A1 (en) 2022-04-11 2023-10-19 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
SG44845A1 (en) * 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
GB9326271D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
AU1743795A (en) 1994-02-03 1995-08-21 Scripps Research Institute, The A cassette to accumulate multiple proteins through synthesis of a self-processing polypeptide
EP0784690B1 (de) * 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US6518482B2 (en) * 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
US20020168342A1 (en) * 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
GB9504344D0 (en) * 1995-03-03 1995-04-19 Unilever Plc Antibody fragment production
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6320029B1 (en) * 1996-11-29 2001-11-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
EP1007637B1 (de) * 1997-04-14 2004-06-30 Cell Genesys, Inc. Methoden zur erhöhung der effizienz rekombinanter aav produkte
US7276488B2 (en) * 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
ATE222925T1 (de) 1998-03-12 2002-09-15 Inst Genetics Llc Verbessertes verfahren zur herstellung von faktor viii
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
WO1999061595A2 (en) 1998-05-27 1999-12-02 Cell Genesys, Inc. Adeno-associated viral vector-mediated expression of factor viii activity
US6797505B2 (en) 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1038959A1 (de) * 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
EP1194161B1 (de) 1999-07-13 2005-11-23 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
US6517830B1 (en) * 1999-08-05 2003-02-11 Emory University Compositions and methods for the expression of factor VIII polypeptides and uses therefor
US6933362B1 (en) * 1999-08-17 2005-08-23 Rensselaer Polytechnic Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
JP2003511082A (ja) 1999-10-12 2003-03-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 第ｖｉｉｉ因子をコードするアデノ随伴ウィルスベクターとその使用法
WO2001036650A2 (en) * 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
ES2172383B1 (es) 2000-04-06 2003-12-16 Univ Madrid Autonoma Procedimiento pra la construccion de vectores retrovirales policistronicos.
US6852510B2 (en) * 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
WO2002072024A2 (en) 2001-03-12 2002-09-19 Progenetics Llc Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
JP2005526001A (ja) * 2001-10-04 2005-09-02 アグイラルーコルドバ，カリオス，エスツアルド 遺伝子療法用キメラ型ウイルスベクター
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
US20040249134A1 (en) 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
MXPA04010061A (es) 2002-04-18 2004-12-13 Merck Patent Gmbh Factor viii modificado.
US7211558B2 (en) 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
US20050095705A1 (en) 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20060228336A1 (en) * 2004-10-12 2006-10-12 Derek Ko Human prolyl isomerase 1 (PIN 1) promoter and uses thereof

Also Published As

Publication number Publication date
EP1629095A4 (de) 2006-06-21
CA2525379A1 (en) 2004-12-29
WO2004113493A2 (en) 2004-12-29
US20040265955A1 (en) 2004-12-30
EP1629095B1 (de) 2011-05-25
WO2004113493A3 (en) 2005-03-03
JP2006526410A (ja) 2006-11-24
US7485291B2 (en) 2009-02-03
JP4755586B2 (ja) 2011-08-24
EP1629095A2 (de) 2006-03-01

Similar Documents

Publication Publication Date Title
DE50308030D1 (de) Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
CY1113153T1 (el) ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
ATE330007T1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
ATE341621T1 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
NZ500253A (en) Osteoprotegerin binding proteins and receptors
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
CO5241328A1 (es) Constructo de adn para la obtencion recombinante de saratina
Galanis et al. Duplication of leader sequence for protein targeting to mitochondria leads to increased import efficiency
ATE236259T1 (de) Herstellung einzelner genprodukte eines chimären fusionsproteins durch spaltung mit überall vorkommenden endoproteasen
DE602007011616D1 (de) Verfahren zur herstellung von oligopeptiden
JP2005525128A5 (de)
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
DE60025480D1 (de) Methoden zur identifizierung von modulatoren wechselwirkender proteine
DE60037508D1 (de) Verfahren zur herstellung von rekombinantem insulin durch fusionsproteine
WO2002004630A3 (en) Methods for recombinatorial nucleic acid synthesis
WO2003016477A3 (en) Insect or83b odorant receptor
DE602004028239D1 (de) Protease, für die protease codierende dna und verfahren zur herstellung der protease
WO2003020913A3 (en) Anopheles gambiae odorant receptors and genes
DE60117754D1 (de) Verfahren zur herstellung von rekombinantem trypsin
DE60318882D1 (de) Uroplakin-ii-promotor aus schwein und verfahren zur herstellung nützlicher proteine unter verwendung des promotors
DE60329862D1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties